Pulmonary embolism future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Vishnu Vardhan Serla (talk | contribs)
nocaptcha
13,010 edits
Created page with "__NOTOC__ Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{Pulmonary embolism}} ==References== {{r..."
 
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Bot: Removing from Primary care
 
(8 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{| class="infobox" style="float:right;"
|-
| [[File:Siren.gif|30px|link=Pulmonary embolism resident survival guide]]|| <br> || <br>
| [[Pulmonary embolism resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']]
|}
{{Pulmonary embolism}}
'''Editor(s)-In-Chief:''' {{ATI}}, [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com]; {{AE}} {{Rim}}
 
==Overview==
There are several ongoing studies on future therapies for the prevention of [[venous thromboembolism]] (VTE). The APEX study is a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration [[betrixaban]] with standard of care [[enoxaparin]] for the prevention of [[VTE]] in acute medically ill patients.[http://clinicaltrials.gov/ct2/show/study/NCT01583218?term=APEX+and+betrixaban&rank=1] MARINER is a randomized, double-blind, placebo-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for [[VTE]], which aims to evaluate [[rivaroxaban]] in the prevention of symptomatic [[VTE]] events and VTE-related deaths for a period of 45 days post-hospital discharge.[http://clinicaltrials.gov/ct2/show/study/NCT02111564?term=MARINER&rank=1]
 
==Future or Investigational Therapies==
 
===Phase 3 Trials (of New Treatment Options)===
 
====Acute Medically Ill Venous Thromboembolism (VTE) Prevention With Extended Duration Betrixaban Study (The APEX Study): Sponsored by Portola Pharmaceuticals<ref>http://clinicaltrials.gov/ct2/show/NCT01583218?term=APEX&rank=2</ref>====
* Status: Currently recruiting
* Primary Outcome Measures: Composite of VTE ([[deep vein thrombosis]] (DVT) and/or [[pulmonary embolism]] (PE)) and VTE death
* Secondary Outcome Measures: Number of patients with symptomatic VTE
* Estimated Enrollment: 6,850 patients
* Study Start Date: March 2012
* Estimated Study Completion Date: December 2014
<table>
<tr>
<td>'''Arms'''</td>
<td>'''Assigned Content'''</td>
</tr>
<tr>
<td>Experimental: Betrixaban</td>
  <td>Drug: Betrixaban: Betrixaban 80 mg PO QD for 35 day + seven days/Enoxaparin Placebo: Once daily, 6-14 days</td>
</tr>
<tr>
<td>Active Comparator: Enoxaparin</td>
<td>Drug: Enoxaparin: Enoxaparin 40 mg SC QD for 10 ± four days/Betrixaban Placebo: once daily, 35 days</td>
</tr>
</table>
 
====A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)<ref>https://clinicaltrials.gov/ct2/show/NCT02111564?term=MARINER&rank=1</ref>====
* Status: Currently recruiting
* Primary Outcome Measures: Occurrence of symptomatic venous thromboembolism event (VTE) and VTE-related death
* Estimated Enrollment: 8000
* Study Start Date: June 2014
* Estimated Study Completion Date: February 2017
<table>
<tr>
<td>'''Arms'''</td>
<td>'''Assigned Content'''</td>
</tr>
<tr>
<td>Experimental: Rivaroxaban</td>
<td>Drug: Drug: Rivaroxaban, 10 mg - Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening >= 50 mL/min will receive 10 mg rivaroxaban tablet with or without food.<br>
Drug: Rivaroxaban, 7.5 mg- Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from 30 to 49 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
</tr>
<tr>
<td>Placebo Comparator: Placebo</td>
<td>Drug: Placebo</td>
</tr>
</table>
 
====Efficacy and Safety Study of Apixaban for Extended Treatment of DVT or PE: Sponsored by Bristol-Myers Squibb and Pfizer <ref>http://clinicaltrials.gov/ct2/show/NCT00633893</ref>====
* Status: Currently recruiting
* Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
* Secondary Outcome Measures: Bleeding
* Estimated Enrollment: 2,430 patients
* Study Start Date: May 2008
* Estimated Study Completion Date: August 2012
{|
|-
|'''Arms'''
|'''Assigned Content'''
|-
| Experimental: 1 - 2.5 mg
| Drug: Apixaban - Tablets, Oral, twice daily, 12 months (Other Name: BMS-562247)
|-
| Experimental: 2 - 5 mg
| Drug: Apixaban - Tablets, Oral, twice daily, 12 months (Other Name: BMS-562247)
|-
| Active Comparator: 3
| Drug: Drug: Placebo - Tablets, Oral, twice daily, 12 months
|}
 
====Prolonged Anticoagulation After a First Episode of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP): Sponsored by University Hospital, Brest<ref>http://clinicaltrials.gov/ct2/show/NCT00740493?term=deep+vein+thrombosis&rank=16</ref>====
* Status: Currently recruiting
* Primary Outcome Measures: Symptomatic recurrent VTE and serious bleeding
* Secondary Outcome Measures: Mortality due to another cause than recurrent VTE or serious bleeding
* Estimated Enrollment: 374 patients
* Study Start Date: July 2007
* Estimated Study Completion Date: November 2013
{|
|-
|'''Arms'''
|'''Assigned Content'''
|-
| Active Comparator: 1 - 18 months of active warfarin therapy
| Drug: Warfarin - 18 months of warfarin therapy
|-
| Placebo Comparator: 2 - 18 months of placebo of warfarin
| Drug: Placebo of warfarin - 18 months of placebo of warfarin therapy
|}


{{Pulmonary embolism}}
====Comparison of Subcutaneous Heparin and Enoxaparin for DVT Prophylaxis in Surgical Intensive Care Patients: Sponsored by William Beaumont Hospitals<ref>http://clinicaltrials.gov/ct2/show/NCT01325779?term=deep+vein+thrombosis&rank=17</ref>====
* Status: Currently recruiting
* Primary Outcome Measures: Development of lower extremity DVT
* Secondary Outcome Measures: Adverse events associated with use of subcutaneous heparin and enoxaparin
* Estimated Enrollment: 400 patients
* Study Start Date: March 2011
* Estimated Study Completion Date: December 2014
{|
|-
|'''Arms'''
|'''Assigned Content'''
|-
| Active Comparator: Subcutaneous heparin
| Drug: Heparin - subcutaneous heparin 5000 units every eight hours
|-
| Active Comparator: Subcutaneous enoxaparin
| Drug: Enoxaparin - subcutaneous enoxaparin 40 milligrams every 24 hours
|}


==References==
==References==
{{reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}
 
[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Hematology]]
[[Category:Hematology]]
Line 12: Line 130:
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Intensive care medicine]]
[[Category:Primary care]]
{{WH}}
{{WS}}

Latest revision as of 23:53, 29 July 2020
Resident
Survival
Guide

Pulmonary Embolism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pulmonary Embolism from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

Assessment of Clinical Probability and Risk Scores

Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores

History and Symptoms

Physical Examination

Laboratory Findings

Arterial Blood Gas Analysis

D-dimer

Biomarkers

Electrocardiogram

Chest X Ray

Ventilation/Perfusion Scan

Echocardiography

Compression Ultrasonography

CT

MRI

Treatment

Treatment approach

Medical Therapy

IVC Filter

Pulmonary Embolectomy

Pulmonary Thromboendarterectomy

Discharge Care and Long Term Treatment

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Follow-Up

Support group

Special Scenario

Pregnancy

Cancer

Trials

Landmark Trials

Case Studies

Case #1

Pulmonary embolism future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulmonary embolism future or investigational therapies

CDC on Pulmonary embolism future or investigational therapies

Pulmonary embolism future or investigational therapies in the news

Blogs on Pulmonary embolism future or investigational therapies

Directions to Hospitals Treating Pulmonary embolism future or investigational therapies

Risk calculators and risk factors for Pulmonary embolism future or investigational therapies

Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

There are several ongoing studies on future therapies for the prevention of venous thromboembolism (VTE). The APEX study is a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration betrixaban with standard of care enoxaparin for the prevention of VTE in acute medically ill patients.[3] MARINER is a randomized, double-blind, placebo-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for VTE, which aims to evaluate rivaroxaban in the prevention of symptomatic VTE events and VTE-related deaths for a period of 45 days post-hospital discharge.[4]

Future or Investigational Therapies

Phase 3 Trials (of New Treatment Options)

Acute Medically Ill Venous Thromboembolism (VTE) Prevention With Extended Duration Betrixaban Study (The APEX Study): Sponsored by Portola Pharmaceuticals[1]

  • Status: Currently recruiting
  • Primary Outcome Measures: Composite of VTE (deep vein thrombosis (DVT) and/or pulmonary embolism (PE)) and VTE death
  • Secondary Outcome Measures: Number of patients with symptomatic VTE
  • Estimated Enrollment: 6,850 patients
  • Study Start Date: March 2012
  • Estimated Study Completion Date: December 2014
Arms Assigned Content
Experimental: Betrixaban Drug: Betrixaban: Betrixaban 80 mg PO QD for 35 day + seven days/Enoxaparin Placebo: Once daily, 6-14 days
Active Comparator: Enoxaparin Drug: Enoxaparin: Enoxaparin 40 mg SC QD for 10 ± four days/Betrixaban Placebo: once daily, 35 days

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)[2]

  • Status: Currently recruiting
  • Primary Outcome Measures: Occurrence of symptomatic venous thromboembolism event (VTE) and VTE-related death
  • Estimated Enrollment: 8000
  • Study Start Date: June 2014
  • Estimated Study Completion Date: February 2017
Arms Assigned Content
Experimental: Rivaroxaban Drug: Drug: Rivaroxaban, 10 mg - Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening >= 50 mL/min will receive 10 mg rivaroxaban tablet with or without food.

Drug: Rivaroxaban, 7.5 mg- Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from 30 to 49 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.

Placebo Comparator: Placebo Drug: Placebo

Efficacy and Safety Study of Apixaban for Extended Treatment of DVT or PE: Sponsored by Bristol-Myers Squibb and Pfizer [3]

  • Status: Currently recruiting
  • Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
  • Secondary Outcome Measures: Bleeding
  • Estimated Enrollment: 2,430 patients
  • Study Start Date: May 2008
  • Estimated Study Completion Date: August 2012
Arms Assigned Content
Experimental: 1 - 2.5 mg Drug: Apixaban - Tablets, Oral, twice daily, 12 months (Other Name: BMS-562247)
Experimental: 2 - 5 mg Drug: Apixaban - Tablets, Oral, twice daily, 12 months (Other Name: BMS-562247)
Active Comparator: 3 Drug: Drug: Placebo - Tablets, Oral, twice daily, 12 months

Prolonged Anticoagulation After a First Episode of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP): Sponsored by University Hospital, Brest[4]

  • Status: Currently recruiting
  • Primary Outcome Measures: Symptomatic recurrent VTE and serious bleeding
  • Secondary Outcome Measures: Mortality due to another cause than recurrent VTE or serious bleeding
  • Estimated Enrollment: 374 patients
  • Study Start Date: July 2007
  • Estimated Study Completion Date: November 2013
Arms Assigned Content
Active Comparator: 1 - 18 months of active warfarin therapy Drug: Warfarin - 18 months of warfarin therapy
Placebo Comparator: 2 - 18 months of placebo of warfarin Drug: Placebo of warfarin - 18 months of placebo of warfarin therapy

Comparison of Subcutaneous Heparin and Enoxaparin for DVT Prophylaxis in Surgical Intensive Care Patients: Sponsored by William Beaumont Hospitals[5]

  • Status: Currently recruiting
  • Primary Outcome Measures: Development of lower extremity DVT
  • Secondary Outcome Measures: Adverse events associated with use of subcutaneous heparin and enoxaparin
  • Estimated Enrollment: 400 patients
  • Study Start Date: March 2011
  • Estimated Study Completion Date: December 2014
Arms Assigned Content
Active Comparator: Subcutaneous heparin Drug: Heparin - subcutaneous heparin 5000 units every eight hours
Active Comparator: Subcutaneous enoxaparin Drug: Enoxaparin - subcutaneous enoxaparin 40 milligrams every 24 hours

References

  1. ↑ http://clinicaltrials.gov/ct2/show/NCT01583218?term=APEX&rank=2
  2. ↑ https://clinicaltrials.gov/ct2/show/NCT02111564?term=MARINER&rank=1
  3. ↑ http://clinicaltrials.gov/ct2/show/NCT00633893
  4. ↑ http://clinicaltrials.gov/ct2/show/NCT00740493?term=deep+vein+thrombosis&rank=16
  5. ↑ http://clinicaltrials.gov/ct2/show/NCT01325779?term=deep+vein+thrombosis&rank=17

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Pulmonary_embolism_future_or_investigational_therapies&oldid=1642617"